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Abstract
Stem cell factor (SCF) and its receptor c-Kit have been implicated in tissue remodelling and fibrosis. Alveolar
fibroblasts from patients with diffuse interstitial fibrosis secrete more SCF. However, its precise role remains
unclear. In this study the potential role of the SCF–c-Kit axis in pulmonary fibrosis was examined. Fibrosis
was induced by intratracheal instillation of bleomycin (BLM), which caused increased SCF levels in plasma,
bronchoalveolar lavage fluid (BALF) and lung tissue, as well as increased expression by lung fibroblasts.
These changes were accompanied by increased numbers of bone marrow-derived c-Kit+ cells in the lung,
with corresponding depletion in bone marrow. Both recombinant SCF and lung extracts from BLM-treated
animals induced bone-marrow cell migration, which was blocked by c-Kit inhibitor. The migrated cells
promoted myofibroblast differentiation when co-cultured with fibroblasts, suggesting a paracrine pathogenic
role. Interestingly, lung fibroblast cultures contained a subpopulation of cells that expressed functionally active
c-Kit, which were significantly greater and more responsive to SCF induction when isolated from fibrotic lungs,
including those from patients with idiopathic pulmonary fibrosis (IPF). This c-Kit+ subpopulation was αSMA-
negative and expressed lower levels of collagen I but significantly higher levels of TGFβ than c-Kit-negative cells.
SCF deficiency achieved by intratracheal treatment with neutralizing anti-SCF antibody or by use of KitlSl/KitlSl-d
mutant mice in vivo resulted in significant reduction in pulmonary fibrosis. Taken together, the SCF–c-Kit
pathway was activated in BLM-injured lung and might play a direct role in pulmonary fibrosis by the recruitment
of bone marrow progenitor cells capable of promoting lung myofibroblast differentiation.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a progres-
sive, usually fatal lung disease of unknown aetiol-
ogy, characterized by the accumulation of fibrob-
lasts/myofibroblasts with aberrant remodelling of the
lung parenchyma. Fibroblasts represent the key source
of interstitial collagens; however, the mechanisms
underlying the emergence of these cells and their differ-
entiation into myofibroblasts are not fully understood.
There is mounting evidence that bone marrow (BM)-
derived cells are chemotactically recruited to the lung
in response to signals released in reaction to lung
injury and may play important roles in the process of
repair and fibrosis [1]. Some of these cells have been
implicated as extrapulmonary sources of fibroblasts or
fibroblast-like cells capable of elaborating factors to
promote myofibroblast differentiation from endogenous
lung fibroblasts. Hence, improved understanding of the
signals responsible for the recruitment and activation
of bone marrow derived cells would be of great benefit
to current understanding of the fibrotic process.
Stem cell factor (SCF) is expressed as soluble or
membrane-bound forms and promotes survival, prolif-
eration, mobilization from the bone marrow and adhe-
sion of haematopoietic stem cells and other progenitor
cells through binding with its cognate receptor, c-Kit
[2–6]. Recent studies of multiple tissues, including the
liver, kidney, heart and brain, indicate that the SCF–c-
Kit axis is important for tissue remodelling and fibrosis
[7–12]. In the lung their potential importance in IPF is
suggested by a study showing that alveolar fibroblasts
from patients with diffuse interstitial fibrosis secrete
more SCF than cells from sarcoidosis patients [13]. In a
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murine model of asthma, neutralization of SCF in vivo
significantly attenuated airway remodelling and colla-
gen deposition, and strongly suppressed the recruitment
of BM-derived collagen I-expressing cells to the lung
[14]. This may be dependent on fibrogenic factor pro-
duction by SCF-responsive cells, such as eosinophils
and mast cells, but a direct role for SCF–c-Kit in
recruitment and activation of BM-derived fibroblast-
like cells has not been excluded. These findings pro-
vide a compelling argument for further examination of
the essential role of the SCF–c-Kit axis in pulmonary
fibrosis.
In this study, these findings were extended to lung
parenchymal fibrosis, using the bleomycin (BLM)-
induced model to provide evidence that the SCF–c-Kit
pathway was activated and might play a direct role in
pulmonary fibrosis by the recruitment of c-Kit+ bone
marrow cells to sites of lung. The essential role of
this pathway was demonstrated by reduced fibrosis in
mice with SCF deficiency, due either to neutralizing
antibody treatment or a genetic defect.
Materials and methods
Detailed methods are described in Supplementary
materials and methods (see Supplementary material).
Animals
Female C57BL/6, FVB/NJ and GFP transgenic
mice (C57BL/6 or FVB/NJ background) were
purchased from the Jackson Laboratory (Bar Har-
bor, ME, USA) and female Fisher 344 rats were
purchased from Charles River Breeding Lab-
oratories (Wilmington, MA, USA). GFP bone
marrow chimera mice were prepared as before [15].
C57BL/6J-Tg[COL1α2–CreER(T)] mice, carrying
a Cre-recombinase under control of a regulatory
sequence from the α2(I) collagen gene, were a
generous gift from Dr Benoit de Crombrugghe of the
University of Texas MD Andersen Cancer Center [16].
WCB6F1/J KitlSl KitlSld mice were purchased from the
Jackson Laboratory. All animal studies were reviewed
and approved by the University Committee on Use
and Care of Animals at the University of Michigan.
Induction of pulmonary fibrosis
Animals were intratracheally injected with bleomycin
(Blenoxane; Mead Johnson, Princeton, NJ, USA) at
a dose of 2.5 U/kg body weight for mice and 7.5
U/kg body weight for rats, as before [17]. The control
group received the same volume of phosphate-buffered
saline (PBS) only. Where indicated, SCF-treated mice
received recombinant SCF (R&D systems, Minneapo-
lis, MN, USA) intratracheally at a dose of 0.1 µg/g
body weight.
Human lung fibroblasts
Human lung fibroblasts from IPF patients and control
subjects were generously provided by Dr Antonio
Xaubet (Universitat de Barcelona, Spain) and Dr Carol
Feghali-Bostwick (University of Pittsburgh, PA, USA).
Cell migration assay
Assays were performed using a 24-well cell migration
kit (Corning, Lowell, MA, USA), according to the
instruction manual. Freshly isolated whole BM cells
were incubated with Calcein-AM (BD Biosciences)
for 30 min at 37◦C before assay. After 4 h at 37◦C,
the migrated cells were collected for fluorescence
measurements using a Gemini EM (Molecular Devices)
plate reader.
Statistics
Differences between means of various treatments were
assessed for statistical significance by ANOVA, fol-
lowed by post hoc analysis using Scheffe´’s test for
comparison between any two groups; p < 0.05 was
considered significant.
Results
SCF expression was induced in BLM-induced
pulmonary fibrosis
The rodent pulmonary fibrosis model was induced as
before [17] and at the indicated time points bron-
choalveolar lavage fluid (BALF), plasma and lung
tissue samples were collected for analysis of SCF
expression. The results showed that SCF protein was
undetectable in BALF from control mice, as deter-
mined by ELISA, but was highly induced in samples
from BLM-treated mice at all the indicated time points
(Figure 1A). Similar assay of serum samples indicated
significantly elevated levels of SCF in BLM-treated
animals relative to controls (Figure 1B). These deter-
minations detected only soluble SCF; however, for the
lung tissue samples both soluble and membrane-bound
forms were analysed by western blotting. In control
and BLM-treated lung samples both membrane-bound
and soluble forms were detectable (Figure 1C). The
membrane-bound product contains a proteolytic cleav-
age site encoded by exon 6 and post-translational pro-
cessing at this site results in the soluble form. While
membrane-bound SCF was slightly reduced in BLM-
treated lung samples, the soluble form was increased
relative to the control samples at all time points, with
the highest increase at days 3–7 (Figure 1C). How-
ever, these differences in lung SCF protein levels in
response to BLM treatment were not reflected in SCF
mRNA levels, which were not significantly different
between the BLM-treated versus control samples (data
not shown), suggesting that the increase in lung sol-
uble SCF was predominantly due to post-translational
processing.
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Figure 1. SCF expression in BLM-induced pulmonary fibrosis. BALF- (A), serum- (B), lung tissue- (C) and lung fibroblast-conditioned media
(E) samples were obtained from mice at days 3, 7 and 14 after saline (SAL) or BLM treatment. Flow-sorted cells on the basis of the indicated
marker expression from single-cell suspensions of lung tissue (D) were obtained from mice at day 21 after BLM treatment. Samples were
analysed for SCF by ELISA (A, B, E), western blotting (C) or real-time PCR (D). Values represent mean ± SE (n= 5); *statistical significance
(p< 0.05) when compared to respective saline controls.
To determine the cellular source of lung SCF expres-
sion, whole-lung, single-cell suspensions from BLM-
treated mice were sorted to purify cells on the basis of
CD3 (T-cells) or CD11b (inflammatory cells) expres-
sion, or absence of both markers (CD3– /CD11b– ).
When the sorted cells were analysed for SCF mRNA
by real-time PCR, expression was essentially limited
to the double-negative cells, which was over 100-
fold higher than in CD3- or CD11b-positive cells
(Figure 1D). These findings suggested that primarily
structural cells, instead of inflammatory/immune cells,
were the main cellular source of SCF in BLM-induced
pulmonary fibrosis. Fibroblasts are known to express
SCF [13,14]. The ELISA results showed that soluble
SCF was significantly increased in conditioned media
of lung fibroblasts from day 7 and day 14 BLM-treated
animals, relative to those from their respective control
animals (Figure 1E), suggesting that lung fibroblasts
were an important source of SCF in the BLM model.
SCF-induced migration of c-Kit+ BM cells to the
lung
Immunostaining for c-Kit showed infiltration by c-Kit+
cells in lungs of BLM treated mice, whereas only rare
c-Kit+ cells were observed in those from saline or
BLM-treated KitlSl/KitlSl-d mutant mice (Figure 2A).
These mutant mice are compound heterozygotes of
a null SCF mutation (Sl) and the Steel-Dickie (Sld)
mutation, which lacks membrane-bound SCF and
exhibit reduced serum levels of soluble SCF [12] (see
Supplementary material, Figure S1). Thus c-Kit+ cell
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infiltration in this fibrosis model depended on an intact
SCF–c-Kit axis.
Given the increased levels of SCF and c-Kit+ cells
in BLM-injured lung, a direct role of the SCF–c-Kit
axis in homing of BM cells to the injured lung was
examined. After intratracheal treatment with saline,
BLM or recombinant SCF, BM cells and whole lung
cells were analysed for c-Kit+ cells by flow cytometry.
Notably, the results showed increased numbers of
c-Kit+ cells in the lung, which correlated with a
concomitant decrease of such cells in the BM after
BLM or SCF treatment (Figure 2B). This pattern
of changes in the percentage of c-Kit+ cells in the
two compartments would be consistent with induced
migration of these cells from the BM to the lung as a
result of treatment with either BLM or SCF. We further
evaluated this possibility by using GFP BM chimeric
mice. After stable engraftment the mice were treated
with saline or BLM, and 7 days later the lung cells
were analysed for GFP and c-Kit expression by flow
cytometry. The results confirmed that the increased
portion of c-Kit+ cells in the injured lung was derived
from BM on the basis of GFP expression (Figure 2C).
An in vitro assay using modified Boyden chambers
was undertaken to see whether SCF was chemotactic
for bone marrow cells. As shown in Figure 3, SCF
exerted a robust effect on migration of freshly isolated
rat BM cells. This effect was abolished by suppression
of c-Kit expression, using c-Kit siRNA (Figure E2)
or c-Kit kinase inhibitor, imatinib. Interestingly, lung
tissue extracts from control animals did not affect BM
cell migration, whereas extracts from the BLM group
mimicked the effect of SCF, which was also suppressed
by c-Kit siRNA pretreatment, suggesting the effect in a
SCF-dependent manner. These findings confirmed the
ability of pure SCF and SCF in lung extracts of BLM-
treated animals to directly increase the c-Kit-dependent
migratory activity of BM cells.
Figure 2. Qualitative and quantitative analyses of c-Kit+ cells. (A) Immunofluorescent staining of c-Kit (red) in a representative lung
tissue from WT and Sl/Sld mice at day 21 after SAL/BLM treatment, with DAPI (blue) counterstain. Arrows indicate c-Kit+ cells; ×20
magnification. (B) Flow-cytometry analysis of c-Kit+ cells in bone marrow and lungs from WT mice at days 3, 7 and 14 after BLM treatment
or 1 day after recombinant SCF treatment. The percentage of c-Kit+ cells in each group are shown as mean ± SE in the lower panel bar
graph (n = 5). *Statistical significance (p < 0.05) when compared to corresponding SAL-treated mice. (C) Cells from lungs of GFP–BM
chimeric and non-chimeric (Non-GFP) mice at day 7 after SAL/BLM treatment were similarly analysed for GFP and c-Kit expression.
Flow-cytometry data were generated using FlowJo software.
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Figure 3. Chemotactic activity of rSCF on BM cells. Rat whole bone
marrow cells were placed in the upper wells of modified Boyden
chambers (pore size 5.0 µm) and the indicated test substance
was placed in the bottom well – buffer only (None), SCF (100
ng/ml). Cells were transfected with control siRNA or c-Kit siRNA
the day before assay (+si) or pretreated with c-Kit inhibitor,
imatinib (5 µM; +I). SLT and BLT, lung tissue extracts from day
7 saline or BLM-treated rats, respectively. Values represent mean
± SE (n = 5). *Statistical significance (p < 0.05) when compared
to the respective ’None’ control; **statistical significance when
compared to the respective SCF treatment group; ***significance
when compared to BLT group.
BM-derived c-Kit+ cells promoted myofibroblast
differentiation
c-Kit+ GFP+ cells sorted from lungs of GFP BM
chimera mice were co-cultured in vitro with mouse
lung fibroblasts in a Corning transwell cell culture
system. The pore size of the insert membrane (0.4
µm) would allow for the diffusion of soluble fac-
tors between two cell populations, but prevent the
transfer of any cells or cellular organelles. After 16
h, fibroblasts cultured with c-Kit+ GFP+ cells sorted
from BLM-treated mice expressed greater amounts
of mRNA for both collagen I and α-smooth muscle
actin (αSMA) than did fibroblasts cultured with cells
from saline-treated mice (Figure 4). Pretreatment of
sorted cells with TGFβ siRNA abolished this induc-
tion. Thus these BLM-induced BM-derived c-Kit+
cells represented a source of paracrine factor(s) capa-
ble of promoting myofibroblast differentiation, such
as TGFβ.
Increased c-Kit+ collagen I+ cells in the lung
SCF is reported to recruit c-Kit+ collagen I+ BM-
derived cells [14]. We performed immunostaining
for c-Kit and Cre on lung sections of BLM-treated
Col–Cre mice, which carry a Cre-recombinase under
the control of a regulatory sequence from the α2(I)
collagen gene [16]. Co-localization of c-Kit and Cre
showed the presence of c-Kit+ collagen I+ cells in the
injured lung (Figure 5A, upper panel). Flow-cytometric
analysis confirmed infiltration of c-Kit+ collagen I+
cells in the BLM-treated lung, which was suppressed
in KitlSl/KitlSl-d mutant mice (Figure 5B). Interestingly
Figure 4. Effect of BM-derived lung c-Kit+ cells on collagen I and
αSMA expression in lung fibroblasts. c-Kit+ GFP+ cells sorted from
lungs of GFP bone marrow chimera mice at day 7 after SAL or
BLM treatment were placed in the upper transwell (pore size 0.4
µm) and fibroblasts were seeded at the bottom of the plastic
wells. As a control (Con), lung fibroblasts were placed in inserts.
Some sorted cells from BLM-treated mice were transfected with
TGFβ siRNA the day before assay (BLM + TGFβ siRNA). After
16 h of co-culture, fibroblasts at the bottom of the wells were
collected and analysed for collagen I and αSMA mRNA by real-
time PCR (A) and protein by western blotting (B). Values represent
mean ± SE (n = 3). *Statistically significant (p < 0.05) difference
from the control cells. The western blot is representative of three
independent experiments.
we could detect the presence of c-Kit+ collagen I+ cells
in lung fibroblast cultures (Figure 5A, lower panel,
and C) and the percentage of these cells was signif-
icantly higher in cultures from BLM-treated versus
SAL-treated lungs (2.69% versus 0.96%, respectively;
p < 0.05, n = 5).
Expression of c-Kit in lung fibroblast cultures was
evaluated. Cultures from BLM-treated or control ani-
mals revealed detectable expression of c-Kit by real
time PCR (Figure 6A). Treatment with SCF caused
a significantly higher level (3.2-fold versus 1.5-fold)
in c-Kit mRNA in cells from BLM-treated animals
when compared to the response in cells from controls.
Moreover, higher induction of c-Kit expression by SCF
was noted in lung fibroblast cultures isolated from
IPF patients compared to cells from control subjects
(Figure 6B), suggesting that this might be a property of
fibroblast cultures from fibrotic lungs. The expressed c-
Kit was functionally active, since SCF treatment caused
rapid phosphorylation of this receptor, peaking at about
5 min and sustained for at least 10 min (Figure 6C).
Notably, when compared to the predominantly c-Kit–
Copyright  2013 Pathological Society of Great Britain and Ireland. J Pathol 2013; 230: 205–214
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
210 L Ding et al
Figure 5. Analyses of c-Kit+ Collagen I+ cells. (A) Double staining of c-Kit (red) and Cre (green) on lung sections of Col–Cre mice, which
carry a Cre-recombinase under the control of a regulatory sequence from the α2(I) collagen gene (upper panel, ×40 magnification) and
double staining of c-Kit (red) and collagen I (green) on slides of cultured mouse lung fibroblasts (MFb; lower panel, ×20 magnification).
Arrows indicate double-positive cells. DAPI (blue) counterstain. Flow-cytometry analysis of c-Kit and collagen I in (B) lung cells from
wild-type (WT) and Sl/Sld mice and (C) passage 6-cultured lung fibroblasts. All mice were at day 21 after BLM treatment, with a saline
control group (SAL) (B, C).
population, this c-Kit+ subpopulation was essentially
αSMA negative and expressed lower levels of collagen
I but significantly higher levels of TGFβ (Figure 7A,
B). This would be consistent with a paracrine role for
these BM-derived c-Kit+ collagen I+ cells, as sug-
gested above.
SCF deficiency attenuated BLM-induced lung
fibrosis
The importance of this pathway in BLM-induced lung
fibrosis was evaluated in mice made deficient in SCF
by intratracheal treatment with anti-SCF antibodies
or by use of KitlSl/KitlSl-d mutant mice. When sub-
jected to BLM-induced lung injury, the antibody-
treated groups at doses of antibody ≥150 µg/animal
and KitlSl/KitlSl-d mutant mice showed significantly
reduced fibrosis, both morphologically [haematoxylin
and eosin (H&E) or Masson’s trichrome stain] and
biochemically by hydroxyproline analysis (see Sup-
plementary material, Figures S3A, B, S8A, B, respec-
tively). Notably, the reduction in fibrosis by anti-SCF
antibody treatment was accompanied with a signifi-
cant reduction in BLM-induced increase in BM-derived
cells in the lung (see Supplementary material, Figure
S3C). These data, taken together, indicated an essential
role for the SCF–c-Kit signalling pathway in BLM-
induced pulmonary fibrosis.
Discussion
Recent studies suggest that organ injury is ’sensed’
distally in the bone marrow by cells that can migrate
to the site of damage and undergo differentiation to
aid in repair or promotion of fibrosis [18]. However,
the nature of the signal(s) from the injured distal
organ and the mechanism of sensing, as well as
recruitment from the bone marrow, have not been
fully elucidated in the case of pulmonary fibrosis.
Induced lung SCF expression plays an essential role
in airway remodelling in an allergic airway disease
model [14]. In addition, alveolar fibroblasts from IPF
patients secrete more SCF [13]. Thus, ample evidence
is available to suggest the potential importance of the
SCF–c-Kit pathway in pulmonary fibrosis. In this study
the significance of the SCF–c-Kit signal pathway was
investigated with respect to recruitment of BM-derived
cells in the context of BLM-induced lung injury and
fibrosis.
The findings revealed a coincident increase in
expression of SCF at the site of lung injury and
in the level of circulating SCF as early as day 3
after bleomycin treatment. This is comparable to
observations in brain injury, myocardial infarction,
serum nephrotoxic nephritis and wire-induced vascular
injury, wherein SCF expression is also increased
during injury and repair [8–10,12]. It is noteworthy
Copyright  2013 Pathological Society of Great Britain and Ireland. J Pathol 2013; 230: 205–214
Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com
SCF-c-Kit pathway and bleomycin-induced pulmonary fibrosis 211
Figure 6. c-Kit expression and phosphorylation induced by SCF in
lung fibroblasts. (A) Lung fibroblasts from saline (NRF) or BLM-
treated rats were treated with or without SCF (100 ng/ml) and
then analysed for c-Kit mRNA by real-time PCR. In (B) human
lung fibroblasts from controls (CON) or IPF patients were similarly
treated and analysed. The effect of SCF on c-Kit phosphorylation in
BRFs was analysed by western blotting (C). Values represent mean
± SE (n = 5). *Statistically significant (p < 0.05) difference from
the respective untreated control cells.
that increased soluble SCF was mainly regulated at the
level of post-translational processing, consistent with
results reported on the role of SCF in the remodelling
process associated with nephrotoxic nephritis [8].
BLM-induced responses are known to include induc-
tion of some proteinases, such as MMP-2 and MMP-9
[19], which has the capacity to mediate cleavage of
membrane-bound SCF with release into the intersti-
tium and blood circulation as a soluble mediator, as
observed in the BM niche [20] and vascular injury [12].
Current concepts of tissue repair and fibrotic process
implicate the recruitment of BM-derived fibroblast-like
cells to sites of injury in response to chemokine signals
released from the injured tissue [21]. Here our evi-
dence suggested that BLM-induced release of soluble
SCF from the structural cells of the lung resulted in ele-
vated levels of circulating SCF in plasma, which played
a significant role in the recruitment of c-Kit+ cells from
Figure 7. Gene expression analysis of c-Kit+ versus c-Kit– cells in
cultured lung fibroblasts. Lung fibroblast cultures fromBLM-treated
mice were flow-sorted into c-Kit+ and c-Kit– subpopulations. The
separated cells were then analysed for expression of the indicated
genes by qRT–PCR (A) and western blotting (B). Values represent
mean ± SE (n = 3). *Statistically significant (p < 0.05) difference
from the mean value for the respective c-kit– cells. The western
blot was representative of three independent experiments.
BM to the injured lung. The concomitantly decreased
c-Kit+ cells in the BM suggested that normal hom-
ing of circulating progenitor cells is disrupted. C-Kit,
considered as a marker for BM-derived haematopoietic
stem cells, is also expressed on mast cells and dendritic
cells [22–24]. However, mast cell participation was
limited or negligible in our BLM-induced pulmonary
fibrosis model, according to expression of the mast cell
marker, tryptase (data not shown). The role of dendritic
cells remains to be specifically elucidated. We showed
here that BM-derived c-Kit+ cells are capable of elabo-
rating factors to promote myofibroblast differentiation
and thus play a paracrine pro-fibrotic role. Some of
these cells appear to be the c-Kit+ collagen I+ cells
that were isolated along with lung fibroblasts, whose
numbers were increased when isolated from fibrotic
lungs. While they expressed type I collagen, these BM-
derived cells, unlike lung fibroblasts, cannot undergo
myofibroblast differentiation, as previously shown
[14,25]. In contrast, fibrocytes are not known to express
c-Kit but can undergo myofibroblast differentiation and
thus are capable of contributing to matrix deposition
directly [26]. While exogenous BM-derived mesenchy-
mal stem cells (MSCs) protect against lung injury
[27,28], endogenous recruitment of BM-derived cells,
such as fibrocytes, mediated by the SDF-1/CXCR4 axis
is reported to promote pulmonary fibrosis [26,29,30].
BM cell trafficking by SDF-1–CXCR4 is modulated
by c-Kit and its phosphorylation [31]. This crosstalk
between the SDF-1–CXCR4 and SCF–c-Kit signalling
pathways favours the profibrotic role of the recruited
endogenous BM c-Kit+ cells, as observed previously
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Figure 8. Effect of SCF deficiency on BLM-induced pulmonary fibrosis. Wild-type (WT) and SCF-deficient (Sl/Sld) mice were treated with
saline (SAL) or BLM on day 0 and the lungs were harvested 21 days later. A representative Masson’s trichrome-stained lung tissue section
from each treatment group is included in the composite in (A) (×20 magnification). Fibrosis was quantitated biochemically as lung
hydroxyproline content (B); mean ± SD, n = 3; *p < 0.05 compared to the WT saline-treated control mean; **p < 0.05 compared to the
WT BLM-treated group.
for fibrocytes [26,29,30]. In this study, expression of
c-Kit on some cells in cultured fibroblasts was signif-
icantly greater and more responsive to SCF induction
in cells from fibrotic lungs, including those from IPF
patients, which has been previously reported [32]. This
would be consistent with the paracrine role of these
c-Kit+ cells in promoting the elevated myofibroblast
differentiation in fibroblasts isolated from fibrotic lung
tissue. Moreover, recruitment of haematopoietic stem
cells and endothelial progenitor cells via activation of
the SCF-c-Kit signalling pathway is shown to be essen-
tial for osteogenesis [11], a remodelling process akin
to fibrosis, wherein the key participating cell type, the
osteoblast, is viewed as the counterpart of a fibroblast
[33]. In this regard, the role of SCF–c-Kit in osteogen-
esis is highly reminiscent of that in pulmonary fibrosis
in the BLM model.
Direct in vivo confirmation of the role of SCF–c-Kit
in pulmonary fibrosis was provided by animal models.
Imatinib was found to have anti-fibrotic activity in the
BLM-induced lung fibrosis model [34,35]. Although
imatinib is a tyrosine kinase inhibitor capable of
suppressing the effect of SCF, it is not specific for
c-Kit. To attain greater specificity, anti-SCF antibodies
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as well as SCF deficiency in KitlSl/KitlSl-d mutant mice
were used, and both strategies resulted in significant
attenuation of BLM-induced pulmonary fibrosis. Taken
together, the findings directly implicate the SCF–c-Kit
axis in the pathogenesis of BLM-induced lung fibrosis,
with activation of the SCF–c-Kit pathway resulting in
the recruitment of cells from the BM compartment to
sites of lung injury, with consequent paracrine activa-
tion of fibroblasts. Elevated c-Kit expression in IPF
lung fibroblast cultures suggests potential relevance to
human pulmonary fibrosis. Thus, attenuation of SCF
expression and function may be an effective therapeutic
modality for treatment of pulmonary fibrosis.
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